Literature DB >> 12688620

Clinical course of cow's milk protein allergy/intolerance and atopic diseases in childhood.

Arne Høst1, Susanne Halken, Hans P Jacobsen, Anne E Christensen, Anne M Herskind, Karin Plesner.   

Abstract

A cohort of 1,749 newborns from the municipality of Odense, born during 1995 at the Odense University Hospital, were followed up prospectively for the development of cow's milk protein allergy/intolerance (CMPA/I) during the first year of life. Once a diagnosis of CMPA/I was confirmed, a milk-free diet was continued until a new milk challenge had shown development of tolerance. All infants with CMPA/I were rechallenged at 12 months of age and, in the event of continued clinical sensitivity to cow's milk protein, controlled rechallenges were performed every 6 months up to 3 years of age; and thereafter every 12 months until the age of 15 years. From the same birth cohort, 276 infants were randomly selected at birth for prospective non-interventional follow-up in order to investigate the natural course of sensitization and development of atopic disease during childhood. Standardized questionnaires on atopic heredity, environmental factors and presence of atopic symptoms were answered at 0, 6, 12 and 18 months and at 5, 10 and 15 years of age. Interviews on atopic history and environmental factors as well as physical examination were carried out at 18 months, 5, 10 and 15 years of age. Skin prick test and specific sIgE (Pharmacia CAP) testing were performed at 18 months, 5, 10 and 15 years of age against a panel of inhalant allergens (birch, grass, mugwort, dog, cat, horse, Dermatophagoidespteronyssinus, Dermatophagoides farinae, alternaria and cladosporium herbarum). Furthermore, lung function measurements were performed in children when 10 and 15 years of age. Based on controlled milk elimination and challenge procedures, the diagnosis of CMPA/I was confirmed in 39 out of 117 infants, with symptoms suggestive of CMPA/I, thus resulting in a 1-year incidence of CMPA/I of 2.2%. The overall prognosis of CMPA/I was good, with a total recovery of 56% at 1 year, 77% at 2 years, 87% at 3 years, 92% at 5 and 10 years and 97% at 15 years of age. In children younger than 10 years of age, 41% developed asthma and 31% rhinoconjunctivitis. Children with non-IgE-mediated CMPI had a good prognosis, whereas children with IgE-mediated CMPA in early childhood had a significantly increased risk for persistent CMPA, development of other food allergies, asthma and rhinoconjunctivitis. During early infancy, recurrent wheezing was the most prevalent disease (20%), followed by atopic dermatitis (14%) and food allergy (7%) at 18 months of age. Physician diagnosed asthma increased from 2% at 1.5 years of age to 9% at 10 years of age. Rhinoconjunctivitis increased from <1% at 1.5 years of age to 9% at 10 years of age. Overall, the current prevalence of any atopic disease was 20% at 1.5 years of age, declining to 14% at 5 years of age and followed by an increase to 25% at 10 years of age. Sensitization to inhalant and/or food allergens (specific IgE of > or = class 2; CAP RAST) showed a low rate of sensitization among asymptomatics (3%, 10% and 12%) compared with higher rates of sensitization of 8%, 39% and 30% among symptomatic atopics at 1.5, 5 and 10 years of age respectively. The highest rate of sensitization (53%) was found among children with current asthma at 10 years of age.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12688620     DOI: 10.1034/j.1399-3038.13.s.15.7.x

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   6.377


  56 in total

Review 1.  Eczema in early life: genetics, the skin barrier, and lessons learned from birth cohort studies.

Authors:  Jocelyn M Biagini Myers; Gurjit K Khurana Hershey
Journal:  J Pediatr       Date:  2010-08-24       Impact factor: 4.406

Review 2.  Cow's milk protein allergy in children: a practical guide.

Authors:  Carlo Caffarelli; Francesco Baldi; Barbara Bendandi; Luigi Calzone; Miris Marani; Pamela Pasquinelli
Journal:  Ital J Pediatr       Date:  2010-01-15       Impact factor: 2.638

Review 3.  The Heterogeneity of Oral Immunotherapy Clinical Trials: Implications and Future Directions.

Authors:  Christina S K Yee; Rima Rachid
Journal:  Curr Allergy Asthma Rep       Date:  2016-04       Impact factor: 4.806

4.  Children who experience their first fracture at a young age have high rates of fracture.

Authors:  F-J Yeh; A M Grant; S M Williams; A Goulding
Journal:  Osteoporos Int       Date:  2005-09-24       Impact factor: 4.507

5.  Long-term characteristics of hazelnut allergy in an adjuvant-free mouse model.

Authors:  Babu Gonipeta; Sitaram Parvataneni; Pranati Paruchuri; Venu Gangur
Journal:  Int Arch Allergy Immunol       Date:  2010-02-10       Impact factor: 2.749

6.  Cow's milk allergy and neonatal short bowel syndrome: comorbidity or true association?

Authors:  A Diamanti; A G Fiocchi; T Capriati; F Panetta; N Pucci; F Bellucci; G Torre
Journal:  Eur J Clin Nutr       Date:  2014-09-03       Impact factor: 4.016

7.  Investigation of the Efficacy of Lactobacillus rhamnosus GG in Infants With Cow's Milk Protein Allergy: a Randomised Double-Blind Placebo-Controlled Trial.

Authors:  Ahmet Basturk; İshak Isik; Atike Atalay; Aygen Yılmaz
Journal:  Probiotics Antimicrob Proteins       Date:  2020-03       Impact factor: 4.609

Review 8.  IgE-mediated cow's milk allergy in children.

Authors:  Faith Huang; Jennifer S Kim
Journal:  Curr Allergy Asthma Rep       Date:  2012-12       Impact factor: 4.806

Review 9.  How a non-allergist survives an allergy clinic.

Authors:  M Rosenthal
Journal:  Arch Dis Child       Date:  2004-03       Impact factor: 3.791

Review 10.  Food allergy and food intolerance: diagnosis and treatment.

Authors:  Giampiero Patriarca; Domenico Schiavino; Valentina Pecora; Carla Lombardo; Emanuela Pollastrini; Arianna Aruanno; Vito Sabato; Amira Colagiovanni; Angela Rizzi; Tiziana De Pasquale; Chiara Roncallo; Marzia Decinti; Sonia Musumeci; Giovanni Gasbarrini; Alessandro Buonomo; Eleonora Nucera
Journal:  Intern Emerg Med       Date:  2008-08-16       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.